Copper histidine (DrugBank: Histidine, Copper)
2 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
169 | Menkes disease | 2 |
170 | Occipital horn syndrome | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00811785 (ClinicalTrials.gov) | February 27, 2009 | 18/12/2008 | Molecular Bases of Response to Copper Treatment in Menkes Disease, Related Phenotypes, and Unexplained Copper Deficiency | Molecular Bases of Response to Copper Treatment in Menkes Disease, Related Phenotypes, and Unexplained Copper Deficiency | Menkes Disease;Occipital Horn Syndrome;Unexplained Copper Deficiency | Drug: Copper Histidine | Cyprium Therapeutics, Inc. | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);National Center for Complementary and Integrative Health (NCCIH) | Completed | N/A | 80 Years | All | 93 | Phase 3 | United States |
2 | NCT00001262 (ClinicalTrials.gov) | June 1990 | 3/11/1999 | Copper Histidine Therapy for Menkes Diseases | Early Copper Histidine Therapy in Menkes Disease | Kinky Hair Syndrome | Drug: Copper Histidine | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | NULL | Completed | N/A | N/A | All | 60 | Phase 1;Phase 2 | United States |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00811785 (ClinicalTrials.gov) | February 27, 2009 | 18/12/2008 | Molecular Bases of Response to Copper Treatment in Menkes Disease, Related Phenotypes, and Unexplained Copper Deficiency | Molecular Bases of Response to Copper Treatment in Menkes Disease, Related Phenotypes, and Unexplained Copper Deficiency | Menkes Disease;Occipital Horn Syndrome;Unexplained Copper Deficiency | Drug: Copper Histidine | Cyprium Therapeutics, Inc. | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);National Center for Complementary and Integrative Health (NCCIH) | Completed | N/A | 80 Years | All | 93 | Phase 3 | United States |